TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02210208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepitel® Ag
Description: A soft silicone wound contact layer that allows exudates to pass vertically into a secondary absorbent dressing. The product provides fixation and protection of the tissues and has antimicrobial properties.~This silicone net dressing will be used to prevent lifting and adherence of skin grafts to the dressings, as well as to prevent pain, and promote healing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® Transfer Ag
Description: Mepilex® Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.~Mepilex® Transfer Ag consists of a Safetac® adhesive layer and compressed polyurethane foam containing silver sulphate and activated carbon. Safetac® is a unique adhesive technology that minimizes pain to patients and trauma to wounds and the surrounding skin. It minimizes risk for maceration by sealing the wound margins; ensuring exudate does not spread to the surrounding skin.
Study: NCT00605995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: 20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
Study: NCT03901508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS
Description: 20 minutes, 2 electrodes (C3/FP2)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TDCS
Description: 20 minutes, 2 electrodes (C3/FP2)
Study: NCT05080361

Intervention type: DRUG
Intervention: BRAF inhibitor
Description: Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
Study: NCT02401061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
Study: NCT02772809

Intervention type: DEVICE
Group type: OTHER
Intervention: Haptic Robot Therapy with Games
Description: Commercial Joystick and Wheels Plus the Haptic TheraDrive Robot will be used. Haptic Theradrive is a low-cost robotic system for post-stroke upper extremity rehabilitation. The system uses off-the-shelf computer gaming wheels with force feedback to help reduce motor impairment and improve function in the arms of stroke survivors.
Study: NCT02238938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: en-bloc resection
Description: En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: piecemeal resection
Description: Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done.
Study: NCT00605995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
Study: NCT02841345

Intervention type: OTHER
Group type: OTHER
Intervention: behavioral and fMRI
Description: The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~* In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~* In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~* In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants.

Intervention type: OTHER
Group type: OTHER
Intervention: behavioral and fMRI
Description: The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~* In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~* In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~* In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants.

Intervention type: OTHER
Group type: OTHER
Intervention: behavioral and fMRI
Description: The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~* In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~* In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~* In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants.
Study: NCT06462274

Intervention type: OTHER
Intervention: body sample collection and imaging scan

Intervention type: OTHER
Intervention: body sample collection and imaging scan
Study: NCT01304771

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic AKSB
Description: AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide \[FOS\], NutraFlora®).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Synbiotic AKSB
Description: AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide \[FOS\], NutraFlora®).
Study: NCT01491542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®
Description: The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone / CD HORIZON® Spinal System
Description: The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
Study: NCT03344016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contact by clinical center
Description: Patients will be acitvely contacted by the clinical center for follow-up procedure
Study: NCT01538225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks
Study: NCT02104505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Tocopherol 700 mg capsules,
Description: 2 capsules daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safflower oil capsules
Study: NCT00610805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventive Cardiology
Description: Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants will receive usual care per their primary care physician.
Study: NCT01904136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT00356993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioural intervention
Description: Smoking cessation counselling, relapse prevention strategies
Study: NCT03607617

Intervention type: OTHER
Intervention: SDH Tool
Description: The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.

Intervention type: OTHER
Intervention: SDH Tool
Description: The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.

Intervention type: OTHER
Intervention: SDH Tool
Description: The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.

Intervention type: OTHER
Intervention: SDH Tool
Description: The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.

Intervention type: OTHER
Intervention: SDH Tool
Description: The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.

Intervention type: OTHER
Intervention: SDH Tool
Description: The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.
Study: NCT03912974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: see 'arm description'

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: see 'arm description'
Study: NCT00548756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy
Description: Whole Brain Radiation Therapy. Total dose = 30 Gy over 12 fractions at 2.5Gy per fraction.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Patients who did not receive whole brain radiation and develop recurrent disease shall receive treatment based on the number of lesions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaire taking 40 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire taking 40 minutes to complete.
Study: NCT05336981

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Level Light Therapy
Description: The method consists of the application extraoral of low-intensity infrared laser in the major salivary glands-parotid, submandibular

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Low-Level Light Therapy
Description: The method consists of the application extraoral of low-intensity infrared laser in the major salivary glands-parotid, submandibular
Study: NCT01338805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492
Study: NCT04274062

Intervention type: PROCEDURE
Intervention: Integrated Nursing care of placenta previa
Description: Phase I :( preparation phase) Phase II: (Implementation phase) includes Preoperative care , intraoperative care and postoperative care by a nurse.~Phase III: (Evaluation phase)

Intervention type: PROCEDURE
Intervention: Integrated Nursing care of placenta previa
Description: Phase I :( preparation phase) Phase II: (Implementation phase) includes Preoperative care , intraoperative care and postoperative care by a nurse.~Phase III: (Evaluation phase)
Study: NCT01597583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of MobileMedMinder
Description: Use of an intervention to remind patients to take their medications.
Study: NCT03416569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo skin patch + placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: nicotine patch (7 mg/24 hrs) + placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine + Prazosin
Description: nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)
Study: NCT01957592

Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionnaire by interview.
Study: NCT04596098

Intervention type: OTHER
Intervention: Blood sampling
Description: During a care-related blood sampling, patient will provide additional blood sample for research purpuse.

Intervention type: OTHER
Intervention: Blood sampling
Description: During a care-related blood sampling, patient will provide additional blood sample for research purpuse.
Study: NCT05096078

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Special diet program for gestational diabetes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Special diet program for gestational diabetes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The circuit exercise program will consist of a medium-intensity circuit training for 50 minutes, 3 days a week, detailing the main muscle groups of the patients (chest, back, biceps, triceps, deltoid, quadriceps, thigh and calf muscles). Exercise intensity will be monitored using Borg's scale of perceived exertion, with a target intensity of 12 to 14. 8 exercises will be given in a continuous, circuit-type manner with short 1-minute rests.
Study: NCT04595942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Hydrochloride Tablets
Description: Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone Acetate Tablets
Description: Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification
Description: Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
Study: NCT04298099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Given the reproducible efficacy of the erector spinae plane block for thoracic procedures, this pilot study will recruit patients scheduled to undergo thoracic surgery with the adjunct of an erector spinae plane block for perioperative pain. Participants will be assigned sequentially to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Given the reproducible efficacy of the erector spinae plane block for thoracic procedures, this pilot study will recruit patients scheduled to undergo thoracic surgery with the adjunct of an erector spinae plane block for perioperative pain. Participants will be assigned sequentially to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg.
Study: NCT03887247

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-mail Alert
Description: Encrypted email to the following providers: the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager. If there is more than one provider, they are copied together on the same message. The email identifies the concurrent prescriptions, details the patient's prescription history, includes relevant VA/DoD guidelines, states the risk of concurrent prescribing to patient, and provides action steps and relevant resources. When multiple providers are involved, the message encourages the providers to coordinate with each other and provides provider contact information to facilitate this communication.
Study: NCT01361958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC
Study: NCT02416713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellcontrol DriveID
Description: Technology that blocks incoming and outgoing calls and texts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellcontrol DriveID
Description: Technology that blocks incoming and outgoing calls and texts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellcontrol DriveID
Description: Technology that blocks incoming and outgoing calls and texts.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education Only
Description: No active intervention, educational materials will be provided
Study: NCT04470843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Being that adequate pain control is essential to recovery in the post-operative setting, efforts have been made to address this pain at its root. Prior studies have demonstrated that preoperative administration of acetazolamide decreased post-operative referred pain in the immediate post-surgical period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
Study: NCT02424019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILUVIEN 0.19 MG
Study: NCT04680793

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation
Description: The program takes place over a total period of 9 weeks: for 4 weeks they will be cared for two days a week, then after a week's break, for 4 weeks they will be cared for three days a week for a total of approximately 80 hours of care. The program is multidisciplinary and includes: balneotherapy, ergometry, occupational therapy, gymnastics, physiotherapy, walking, sophrology, yoga as well as different workshops for the therapeutic education of the patient led by several professionals (dieticians, physiotherapists, doctors, psychologists).
Study: NCT03550053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D mandibular plate
Description: Patients will be randomly assigned to either have the mandibular plate bent before their surgery, using a 3D model of their mandible or have the mandibular plate bent during their surgery, which is standard of care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D mandibular plate
Description: Patients will be randomly assigned to either have the mandibular plate bent before their surgery, using a 3D model of their mandible or have the mandibular plate bent during their surgery, which is standard of care.